Back to search
FDAFDA · Food and drugs·Recall number D-0567-2025

Duloxetine D/R, 20 mg, 30 Caps, 30-count bottle, RX Only, Packaged & Distributed by: Direct Rx, Dist. By Breckenridge Pharm., Inc., Berlin, CT 06037, NDC 61919-422-30

Published August 13, 2025 · Recall initiated: March 7, 2025

Summary

FDA records drug Class II recall D-0567-2025, published August 13, 2025 and initiated March 7, 2025. Recalling firm: Direct Rx; Status: Ongoing; Reported quantity: 16 bottles; Lot: Lot #: 02AU2406, Exp 01/31/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Direct Rx
Distributor
Nationwide
Lot
Lot #: 02AU2406, Exp 01/31/2027
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Duloxetine D/R, 20 mg, 30 Caps, 30-count bottle, RX Only, Packaged & Distributed by: Direct Rx, Dist. By Breckenridge Pharm., Inc., Berlin, CT 06037, NDC 61919-422-30 recalled?

Yes. FDA published recall D-0567-2025 on August 13, 2025. Reported hazard: CGMP Deviations: Presence of Nitrosamine Drug Substance Related Impurity above the proposed interim limit.

What should I do if I have this product?

Voluntary: Firm initiated · Letter